Senseonics Holdings, Inc. (NASDAQ: SENS)

Senseonics Holdings, Inc. is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system designed to improve diabetes management. The company's primary product, the Eversense CGM system, includes the Eversense E3 and Eversense 365 systems, which measure glucose levels via an implantable sensor, a removable smart transmitter, and a mobile app for real-time monitoring. The Eversense 365 system provides up to twelve months of continuous glucose sensing, while the Eversense E3 system offers six months of use, both requiring minimal user calibration and delivering data through vibratory alerts and Bluetooth connectivity to mobile devices.

Senseonics generates revenue from the sale of its Eversense CGM system, which includes the sensor pack containing the sensor, insertion tool, and adhesive patches; the smart transmitter pack containing the transmitter and charger; and procedure revenue associated with sensor insertion and removal. Revenue is derived through direct sales to distributors and strategic fulfillment partners who supply healthcare providers and patients, as well as through a consignment model with healthcare professionals. The company relies on third-party payor coverage and reimbursement from commercial insurers and government agencies such as Medicare to drive adoption, with approximately 300 million covered lives in the United States as of 2025 through positive coverage decisions including UnitedHealthcare.

The company operates through the following segments:

• Eversense CGM Systems: This segment encompasses the development, manufacturing, and commercialization of implantable continuous glucose monitoring systems for people with diabetes. The segment includes the Eversense E3 CGM system and the Eversense 365 CGM system as its primary products. These systems are designed to provide long-term glucose monitoring with sensor durations of up to six and twelve months, respectively.

Senseonics operates in a competitive CGM market alongside well-capitalized companies such as Dexcom, Medtronic, and Abbott, which also offer FDA-approved and CE Marked CGM systems. The company differentiates itself through the extended duration of its implantable sensor, which lasts up to one year—significantly longer than the seven to 15 days typical of non-implantable CGM systems. Additional competitive advantages include on-body vibratory alerts for glucose thresholds, 24/7 patient and provider support, and the ability to share data remotely with caregivers and healthcare teams.

Senseonics serves people with diabetes, including both type 1 and type 2 patients, who require ongoing glucose monitoring to manage their condition. The company's customers include individuals using insulin pumps or multiple daily injections, as well as those managing diabetes through diet, exercise, and oral medications. Healthcare providers such as endocrinologists, primary care physicians, and certified diabetes educators are also key customers who prescribe the Eversense system and perform sensor insertions and removals.